Current Report Filing (8-k)
February 23 2015 - 8:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
February 23, 2015
Date of Report (Date of
Earliest Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
000-31187 |
870638336 |
(State or other jurisdiction of |
(Commission File |
(IRS Employer Identification |
incorporation) |
Number) |
No.) |
6425 Abrams, Ville St-
Laurent, Quebec, Canada H4S 1X9
(Address of principal executive
offices) (Zip Code)
Registrant's telephone number, including
area code: (514) 331-7440
Check the appropriate box below if the Form 8K fining is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement communication pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx Provides Update on Sales of Forfivo
XL®
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
INTELGENX TECHNOLOGIES CORP.
Dated: February 23, 2015 |
By: /s/ Paul A. Simmons |
|
------------------- |
|
Paul A. Simmons |
|
Chief Financial Officer
|
IntelGenx Provides Update on Sales of Forfivo
XL®
Saint Laurent, Quebec - February 23, 2015 - IntelGenx
Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx", or the Company) today provided
an update on sales and marketing activities for Forfivo XL®, the Companys first
FDA-approved product that was launched in the USA in October 2012 under an
exclusive commercialization agreement with Edgemont Pharmaceuticals LLC
(Edgemont).
According to Symphony Health Solutions, gross sales of Forfivo
XL® totaled $8.9 million in the year ending December 31st, 2014, an
increase of 230% compared with sales of $2.7 million in the preceding year. The
number of Forfivo XL® prescriptions filled increased by 123% from approximately
16,761 in 2013 to 30,378 in 2014. The average month-on-month growth rate of
Forfivo XL® throughout 2014 exceeded 9%.
We are extremely pleased with the growth of Forfivo XL®
throughout 2014 and we believe that this growth will continue, especially as
Edgemont increased its salesforce threefold in mid-December, 2014 stated Dr.
Horst G. Zerbe, President and CEO of IntelGenx. The marketing and sales efforts
that our partner, Edgemont Pharmaceuticals, has invested in the
commercialization of Forfivo XL® have ensured that a more convenient and safe
alternative for patients requiring high-dose anti-depressant therapy is widely
available in the US. Forfivo XL® generated in excess of $1.1 million
(unaudited) of revenue for IntelGenx in 2014 and we anticipate
significantly higher revenue from the product in 2015.
Forfivo XL® is indicated for treatment of Major Depressive
Disorder (MDD) and is the only extended-release bupropion HCl product to provide
a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo
XL® is bupropion, the same active ingredient used in the well-known
antidepressant product: Wellbutrin XL®.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly disintegrating
delivery systems. IntelGenx uses its unique multiple layer delivery system to
provide zero-order release of active drugs in the gastrointestinal tract.
IntelGenx has also developed novel delivery technologies for the rapid delivery
of pharmaceutically active substances in the oral cavity based on its experience
with rapidly disintegrating films. IntelGenx' development pipeline includes
products for the treatment of indications such as severe depression,
hypertension, erectile dysfunction, migraine, insomnia, CNS indications,
idiopathic pulmonary fibrosis, oncology and pain, as well as animal health
products. More information is available about the company at
www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about
IntelGenx' operating results and business prospects that involve substantial
risks and uncertainties. Statements that are not purely historical are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933,
as amended. These statements include, but are not limited to, statements about
IntelGenx' plans, objectives, expectations, strategies, intentions or other
characterizations of future events or circumstances and are generally identified
by the words "may," "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates," "could," "would," and similar expressions. All forward
looking statements are expressly qualified in their entirety by this cautionary
statement. Because these forward-looking statements are subject to a number of
risks and uncertainties, IntelGenx' actual results could differ materially from
those expressed or implied by these forward looking statements. Factors that
could cause or contribute to such differences include, but are not limited to,
those discussed under the heading "Risk Factors" in IntelGenx' annual report on
Form 10-K for the fiscal year ended December 31, 2013, filed with the United
States Securities and Exchange Commission and available at www.sec.gov,
and also filed with Canadian securities regulatory authorities and
www.sedar.com. IntelGenx assumes no obligation to update any such
forward-looking statements.
Each of the TSX Venture Exchange and OTCQX has neither
approved nor disapproved the contents of this press release.
Company Contact:
Dr. Horst G. Zerbe,
President and CEO
IntelGenx
Technologies Corp.
T: +1 514-331-7440 (ext. 201)
F: +1
514-331-0436
horst@intelgenx.com
www.intelgenx.com
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Apr 2023 to Apr 2024